A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn-s Disease: Data From CALM

Colombel, Jean-FredericPanaccione, RemoBossuyt, PeterBaert, FilipVanasek, TomasDanalioglu, AhmetNovacek, GottfriedArmuzzi, AlessandroHebuterne, XavierTravis, SimonDanese, SilvioReinisch, WalterSandborn, William J.Rutgeerts, PaulHommes, DanielSchreiber, StefanNeimark, EzequielHuang, BidanZhou, QianLee, Wan-JuPetersson, JoelWallace, KoriRobinson, Anne M.Thakkar, Roopal B.D'Haens, Geert2020-10-292020-10-292017-10-01http://hdl.handle.net/20.500.12645/25605Colombel J., Panaccione R., Bossuyt P., Baert F., Vanasek T., Danalioglu A., Novacek G., Armuzzi A., Hebuterne X., Travis S., et al., -A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn-s Disease: Data From CALM-, 82nd Annual Scientific Meeting of the American-College-of-Gastroenterology (ACG), Florida, Amerika Birleşik Devletleri, 13 - 18 Ekim 2017, cilt.112A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn-s Disease: Data From CALMConference PaperWOS:00043925900118210.14309/00000434-201710001-00598